About: Serum and fecal profiles of aromatic microbial metabolites reflect gut microbiota disruption in critically ill patients: a prospective observational pilot study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serum and fecal profiles of aromatic microbial metabolites reflect gut microbiota disruption in critically ill patients: a prospective observational pilot study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Serum and fecal profiles of aromatic microbial metabolites reflect gut microbiota disruption in critically ill patients: a prospective observational pilot study
Creator	Beloborodova, Natalia Chernevskaya, Ekaterina Gusarov, Vitaliy Klimenko, Natalia Pautova, Alisa Shilkin, Dmitrii Tyakht, Alexander
Source	Medline; PMC
abstract	BACKGROUND: High serum levels of certain aromatic microbial metabolites (AMM) are associated with severity and mortality in critically ill patients. Omics-based studies suggest gut dysbiosis and reduced microbiome diversity in critical conditions. However, the landscape of gut microbial metabolites is still to be outlined, not to mention the interplay correlation between the metabolome and gut microbiome in critically ill patients. The aim of this study was to analyze the association between serum and fecal levels of AMM and compare them with the composition of gut microbiota in critically ill patients in the acute and chronic stages. METHODS: In this prospective observational pilot study, we analyzed the temporal dynamics of the gut microbiome and the AMM spectrum across two distinct subgroups—acute critical ill (ACI) patients with nosocomial pneumonia and chronically critically ill (CCI) patients (9 subjects each group)—as well as performed comparison with 23 healthy volunteers. The AMM levels for each patient were measured using GC-MS in simultaneously taken serum and fecal samples (SFS). These parameters were compared with 16S rRNA fecal microbiome profiles. RESULTS: The observed proportions of bacterial taxa suggest a significant gut dysbiosis in the ACI and the CCI patients. Stronger imbalance in microbiome composition and dynamics observed in the ACI patients compared to the CCI ones resonates with a higher severity in the former group. The total levels of AMM in serum samples were higher for the ACI patients than for the CCI patients (3.7 (1.4–6.3) and 1.1 (1.0–1.6) μM, respectively; p = 0.0003). The qualitative composition of the SFS was also altered. We discovered significant associations between gut microbial taxa levels and metabolite concentrations in blood serum as well as in feces in each of the ACI and the CCI patients. CONCLUSIONS: Aromatic microbial metabolite profiles in the gut and the serum are interlinked and reflect a disruption of the gut microbial community in critically ill patients.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.1186/s13054-020-03031-0
bibo:pmid	32513224
has license	cc-by
sha1sum (hex)	4c5bce950386b03adc72f9bcbc9041f8f526b54b
schema:url	https://doi.org/10.1186/s13054-020-03031-0
resource representing a document's title	Serum and fecal profiles of aromatic microbial metabolites reflect gut microbiota disruption in critically ill patients: a prospective observational pilot study
has PubMed Central identifier	PMC7278238
has PubMed identifier	32513224
schema:publication	Crit Care
resource representing a document's body	covid:4c5bce950386b03adc72f9bcbc9041f8f526b54b#body_text
is schema:about of	named entity 'compared' named entity 'critical' named entity 'These' named entity 'patient' named entity 'serum' named entity 'gut microbial' named entity 'qualitative' named entity 'microbiome' named entity 'conditions' named entity 'microbiome' named entity 'simultaneously' named entity 'However' named entity 'group' named entity 'subjects' named entity 'feces' named entity 'metabolome' named entity 'compared' named entity 'metabolites' named entity 'ACI' named entity 'studies' named entity 'patients' named entity 'ACI' named entity 'chronic' named entity 'critical' named entity 'patients' named entity 'measured' named entity 'serum' named entity 'dysbiosis' named entity 'GC-MS' named entity 'critically ill' named entity 'Results' named entity 'critically ill patients' named entity 'feces' named entity 'serum levels' named entity '1.1' named entity 'gut microbial' named entity 'metabolome' named entity 'gut microbiome' named entity 'dysbiosis' named entity 'gut microbiome' named entity 'critically ill patients' named entity 'correlation' named entity 'AMM' named entity 'SFS' named entity 'Aromatic' named entity 'gut microbial' named entity 'pilot study' named entity 'critically ill patients' named entity 'acute' named entity 'bacterial' named entity 'metabolic' named entity 'DNA extraction' named entity 'ICU' named entity 'critically ill patients' named entity 'septic shock' named entity 'commensal' named entity 'Serratia' named entity 'bile acids' named entity 'Microbiome' named entity 'resource competition' named entity 'Akkermansia' named entity 'calibration curve' named entity 'Serum samples' named entity 'antibiotics' named entity 'chronic illness' named entity 'homovanillic acid' named entity 'taxa' named entity 'Erysipelotrichaceae' named entity 'metabolite' named entity 'serum' named entity 'capillary' named entity 'WBC' named entity 'gut microbiota' named entity 'biomarkers' named entity 'serum'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software